PPT-Transcatheter Intracardiac Shunt Device Provides Sustained Clinical Benefit at One Year

in Heart Failure with Preserved or Mildly Reduced Ejection Fraction The REDUCE LAP Heart Failure Trial David M Kaye MD PhD on behalf of the REDUCE LAP HF Investigators 1 Disclosures 2 DK is an unpaid member of the Corvia Medical Inc Scientific Advisory Group. . What can be safely done?. Jonas D. Del Rosario, MD, FPCC. Clinical Associate Professor. UP College of Medicine. No disclosures. First DO NO HARM. Objectives. What types of VSD are amenable for catheter closure at this time. HR Specialty Products & Services Catalogue Executive Summary. - A No Frills Distillation of Vendor’s Marketing Collateral -. Thomas A Ference. President & CEO. Human Resources Mining & Distribution Co. To build a . peritoneovenous. (PV) shunt . that can:. Drain . ascitic. fluid from peritoneum into femoral vein (on order of L/week or 30-40 mL/min). Prevent backflow from the femoral vein into the peritoneum (>5% of fluid flows back into peritoneum). Social Reform – Old Age Pensions. 1927 – Government passed the Old Age Pension Act. Max $20/month. Social Reform – Old Age Pensions. Requirements. Must be British subject 70+. Must have lived in Canada for 20+ years and in current province 5+ years. Troy Hounshell, DO. Iowa Heart Center. Heart Rhythm Center. Disclosures . Harvard Clinical Research Institute. Medtronic. Milestone Pharmaceuticals, Inc.. St. Jude Medical. Employee-Iowa Heart Center/Mercy-Des Moines. . RELEASE. DRUG . . DELIVERY . SYSTEM. Sustain Release Drug Delivery System. contents. INTRODUCTION. RATIONALATY IN DESIGNING S.R.D.F.. CONCEPT OF S.R.D.F.. DIFFERENCE BETWEEN C .R. AND S. R. . REPEAT-ACTION Vs SUSTAINED-ACTION DRUG THERAPY.. Drug . Delivery System. In the . conventional therapy. . aliquot quantities of drugs are introduced into the system at specified intervals of time with the result that there is considerable . fluctuation in drug concentration level. ATLAS-CMS Power Working Group,. 08/02/2011. Shunt-LDO reminder. Combination of a LDO and a shunt transistor. Shunt. regulation circuitry . . const . I. load. LDO. regulation loop . . constant V. Steve Black, PhD. Co-Director. , Cardiovascular Discovery Institute & Mitochondrial Bioenergetics Core . Chief, Pulmonary Vascular Disease Program. Vascular Biology Center. Georgia Regents University. Shunts. Denise . Joffe. , MD. Objectives. To explain . intracardiac. shunting using illustrations. To describe the hemodynamic and physiologic consequences of . intracardiac. shunting. Outline. Describe simple (unidirectional) shunts. Jeff Shuren, MD, JD. Center for Devices and Radiological Health. U.S. Food and Drug Administration. www.fda.gov. Who We Are…. CDRH is a team of over 1,700 dedicated, highly-skilled people, including:. Manu Varma, DO. Pediatric Cardiology Fellow. University of Texas Health Science Center at Houston; Houston, TX. Disclosures. None. Ebstein. . Anomaly. Congenital anomaly of the tricuspid valve and right ventricle due to incomplete delamination of tricuspid valve leaflets. Adam Greenbaum, MD. Emory University Hospital, Atlanta. @AdamGreenbaumMD. On behalf of the CLASP TR . study investigators. Speaker Disclosures . Speaker’s name: Adam Greenbaum, MD. ☑ I have the . Gregg W. Stone, MD. On behalf of Michael Mack, William Abraham, JoAnn Lindenfeld . and the COAPT Investigators. Gregg W. Stone MD. Consulting fees from . Neovasc. , Valfix, Gore. Equity/options in . Ancora.